XML 66 R54.htm IDEA: XBRL DOCUMENT v3.25.1
Stockholders’ Deficiency (Details) - USD ($)
3 Months Ended 12 Months Ended
Sep. 24, 2024
Mar. 31, 2025
Mar. 31, 2024
Dec. 31, 2024
Stockholders’ Equity (Deficiency) [Line Items]        
Convertible ratio   1:1    
Derivative, Gain, Statement of Income or Comprehensive Income [Extensible Enumeration]   Warrant liabilities    
Gain on revaluation   $ 523,491  
Derivative, Loss, Statement of Income or Comprehensive Income [Extensible Enumeration]     Warrant liabilities  
Derivative liability, loss on revaluation     $ 619,989  
Revaluation of derivative liability       $ 2,670,386
Unrecognized share-based compensation expense   5,286,397    
Warrants [Member]        
Stockholders’ Equity (Deficiency) [Line Items]        
Gain on revaluation   87,695    
Revaluation of derivative liability   2,123,352   2,646,843
Black-Scholes Option Pricing Model [Member] | Warrants [Member]        
Stockholders’ Equity (Deficiency) [Line Items]        
Estimated fair value for adjustment   415,434   $ 503,129
Derivative [Member]        
Stockholders’ Equity (Deficiency) [Line Items]        
Revaluation of derivative liability   2,133,690    
Public Offering [Member]        
Stockholders’ Equity (Deficiency) [Line Items]        
Gain on revaluation   $ 536,696  
SPA [Member]        
Stockholders’ Equity (Deficiency) [Line Items]        
Purchase of warrant (in Shares) 430,805      
Debenture warrants amount $ 215,421      
Warrant exercise price per share (in Dollars per share) $ 10.55      
2023 Option Plan [Member]        
Stockholders’ Equity (Deficiency) [Line Items]        
Percentage of grant non-transferable share options   20.00%    
2022 Option Plan [Member]        
Stockholders’ Equity (Deficiency) [Line Items]        
Percentage of grant non-transferable share options   10.00%